The global generic oncology sterile injectable market is expected to grow at a significant CAGR during the forecast period (2021-2027). Generic oncology sterile injectables are biologics that have the same active ingredients as the branded version, however, differ solely in the inactive elements. These sterile oncology injectables are used to treat a wide range of cancers, including breast, prostate, colorectal, melanoma, lung, and bronchus cancers. The injectables are commonly used as they are less expensive than branded medications.
Further, manufacturers present in the US are concentrating on releasing new products to provide low-cost therapy to patients which are driving the market. Moreover, Owing to the increasing number of product launches in the US, North America is anticipated to hold a dominating position in the global generic oncology sterile injectable market. For instance, in September 2019, Mylan N.V. announced Fulvestrant Injection, a generic version of AstraZeneca's Faslodex Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe for the treatment of advanced breast cancer in the US. Asia-Pacific is expected to be the fastest-growing region in the market owing to increased measures taken by key players to expand the presence of their injectables in this region.
Market Coverage
Competitive Landscape: Eli Lilly & Co., Mylan N.V., Sandoz International GmbH, and Teva Pharmaceutical Industries Ltd., among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Generic Oncology Sterile Injectable Market by Segment
By Product Type
• Chemotherapy
• Monoclonal Antibodies
• Cytokines
• Peptide Hormones
By Disease Indication
• Ovarian Cancer
• Breast Cancer
• Lung Cancer
• Pancreatic Cancer
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Generic Oncology Sterile Injectable Market by Region
North America
Europe
Asia-Pacific
Rest of the World